Eric Nuermberger, MD

Primary Academic Title

Professor of Medicine

Background

Research Interests

Drug development for tuberculosis and non-tuberculous mycobacterial infections, including Mycobacterium ulcerans disease (Buruli ulcer)

Lab Website

Eric Nuermberger Lab

• Research in the Eric Nuermberger Lab focuses primarily on experimental chemotherapy for tuberculosis. We use proven murine models of active and latent tuberculosis infection to assess the effectiveness of novel antimicrobials. A key goal is to identify new agents to combine with existing drugs to shorten tuberculosis therapy or enable less frequent drug administration. We're also using a flow-controlled in vitro pharmacodynamic system to better understand the pharmacodynamics of drug efficacy and the selection of drug-resistant mutants during exposure to current agents.

Research Summary

Dr. Nuermberger’s primary research interest is the experimental chemotherapy of TB. The work uses validated murine models of active TB and latent TB infection to evaluate the efficacy of promising new drugs and drug regimens. A major goal is to identify new agents that can be combined together in novel regimens or combined with existing drugs to shorten the duration of TB therapy.

A newer interest is to develop improved animal models of non-tuberculous mycobacterial infection to enable a similar approach to drug and regimen development for these difficult-to-treat infections.

PubMed

http://www.ncbi.nlm.nih.gov/pubmed/?term=nuermberger+e

Selected Publications

• Almeida DV, Converse PJ, Omansen TF, Tyagi S, Tasneen R, Kim J, Nuermberger EL. Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. Antimicrob Agents Chemother. 2020;64(6):e00259-20

• Kaushik A, Ammerman NC, Tasneen R, Lachau-Durand S, Andries K, Nuermberger E. Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy. Am J Respir Crit Care Med. 2021 Dec 23. doi: 10.1164/rccm.202012-4541OC. Online ahead of print. PMID: 34939891

• Rifat D, Chen L, Kreiswirth BN, Nuermberger EL. Genome-Wide Essentiality Analysis of Mycobacterium abscessus by Saturated Transposon Mutagenesis and Deep Sequencing. mBio. 2021 Jun 29;12(3):e0104921. doi: 10.1128/mBio.01049-21. Epub 2021 Jun 15. PMID: 34126767

• Rosenthal IM, Zhang M, Williams K, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model, PLoS Medicine, 2007;4:e344

• Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2015; 60:270-7 

Graduate Program Affiliations

• Medicine
• International Health, Johns Hopkins Bloomberg School of Public Health

Memberships

• American Society for Microbiology
• American Thoracic Society
• Infectious Diseases Society of America

Professional Activities

• Drug Discovery and Mechanisms of Antimicrobial Resistance (DDR) Study Section, NIH Center for Scientific Review, Member, 7/16/21
• Scientific Advisory Committee, M√©decins Sans Fronti√®res MDR-TB Clinical Trial Initiative, Member, 10/26/14
• Scientific Advisory Committee, TB Alliance, Member, 11/1/16
• TB Transformative Science Group, AIDS Clinical Trial Group (2011 - 2019), Member, 2/1/21